STOCK TITAN

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

NRx Pharmaceuticals (NRXP) and its wholly-owned subsidiary HOPE Therapeutics announced their participation in the upcoming ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will present at 8:30 AM ET. The conference brings together institutional investors, corporate clients, and industry professionals. The NRx management team will conduct one-on-one investor meetings throughout the day. The presentation will be available via live stream on the NRx Events platform.

NRx Pharmaceuticals (NRXP) e la sua controllata interamente posseduta HOPE Therapeutics hanno annunciato la loro partecipazione alla prossima ThinkEquity Conference il 30 ottobre 2024, presso il Mandarin Oriental Hotel di New York. Il Dr. Jonathan Javitt, Presidente e Chief Scientist di NRx e Co-CEO di Hope, presenterà alle 8:30 AM ET. La conferenza riunisce investitori istituzionali, clienti aziendali e professionisti del settore. Il team di gestione di NRx condurrà incontri individuali con gli investitori durante tutta la giornata. La presentazione sarà disponibile in streaming dal vivo sulla piattaforma NRx Events.

NRx Pharmaceuticals (NRXP) y su filial totalmente propiedad HOPE Therapeutics anunciaron su participación en la próxima ThinkEquity Conference el 30 de octubre de 2024, en el Mandarin Oriental Hotel de Nueva York. El Dr. Jonathan Javitt, Presidente y Científico Jefe de NRx y Co-CEO de Hope, presentará a las 8:30 AM ET. La conferencia reúne a inversores institucionales, clientes corporativos y profesionales de la industria. El equipo de gestión de NRx llevará a cabo reuniones individuales con los inversores durante todo el día. La presentación estará disponible a través de una transmisión en vivo en la plataforma NRx Events.

NRx 제약 (NRXP)과 그 자회사인 HOPE Therapeutics2024년 10월 30일에 뉴욕의 만다린 오리엔탈 호텔에서 열리는 ThinkEquity 회의에 참석할 예정이라고 발표했습니다. NRx의 회장 및 수석 과학자인 Dr. Jonathan Javitt가 오전 8시 30분 ET에 발표할 것입니다. 이 회의는 기관 투자자, 기업 고객 및 업계 전문가들을 모으고 있습니다. NRx 경영진 팀은 하루 종일 투자자와의 일대일 회의를 진행할 예정입니다. 발표는 NRx Events 플랫폼을 통해 생중계될 예정입니다.

NRx Pharmaceuticals (NRXP) et sa filiale entièrement détenue HOPE Therapeutics ont annoncé leur participation à la prochaine ThinkEquity Conference le 30 octobre 2024, à l'Hôtel Mandarin Oriental de New York. Le Dr Jonathan Javitt, Président et Scientifique en Chef de NRx et Co-CEO de Hope, présentera à 8h30 ET. La conférence réunit des investisseurs institutionnels, des clients d'entreprise et des professionnels de l'industrie. L'équipe de direction de NRx tiendra des réunions individuelles avec les investisseurs tout au long de la journée. La présentation sera disponible en streaming en direct sur la plateforme NRx Events.

NRx Pharmaceuticals (NRXP) und ihre vollständig im Besitz befindliche Tochtergesellschaft HOPE Therapeutics haben ihre Teilnahme an der bevorstehenden ThinkEquity Conference am 30. Oktober 2024 im Mandarin Oriental Hotel in New York bekannt gegeben. Dr. Jonathan Javitt, Vorsitzender und Chief Scientist von NRx sowie Co-CEO von Hope, wird um 8:30 Uhr ET präsentieren. Die Konferenz bringt institutionelle Investoren, Unternehmensvertreter und Branchenexperten zusammen. Das Management-Team von NRx wird den ganzen Tag über persönliche Investorenmeetings abhalten. Die Präsentation wird live über die NRx Events-Plattform verfügbar sein.

Positive
  • None.
Negative
  • None.

MIAMI, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.

Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will be presenting at 8:30AM ET on October 30th. Members of the NRx management team will also be holding one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule on-on-one meetings here.

The presentation will also be live-streamed at the following link: NRx Events.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About ThinkEquity
ThinkEquity is a boutique investment bank founded by professionals who have collaborated for over a decade, collectively financing over $50 billion in public and private capital raises, restructurings, and mergers and acquisitions. Past ThinkEquity conferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to connect. To register to attend The ThinkEquity Conference, please follow this link.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com

Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com


FAQ

When is NRx Pharmaceuticals (NRXP) presenting at the ThinkEquity Conference?

NRx Pharmaceuticals (NRXP) will present at the ThinkEquity Conference on October 30, 2024, at 8:30 AM ET at the Mandarin Oriental Hotel in New York.

How can investors attend NRXP's presentation at the ThinkEquity Conference?

Investors can register to attend the conference and schedule one-on-one meetings through the provided registration link, or watch the live-streamed presentation through the NRx Events platform.

Who will represent NRXP at the ThinkEquity Conference 2024?

Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx and Co-CEO of Hope Therapeutics, will lead the presentation, while other NRx management team members will be available for one-on-one meetings.

NRX Pharmaceuticals, Inc.

NASDAQ:NRXP

NRXP Rankings

NRXP Latest News

NRXP Stock Data

14.72M
10.75M
26.51%
4.75%
5.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMINGTON